Avidity biosciences reports third quarter 2024 financial results and recent highlights

Enrollment in global phase 3 harbor™ study for del-desiran in dm1 is on track avidity initiated biomarker cohort for del-brax fortitude™ study for fshd; pursuing a potential accelerated approval path for del-brax reported positive del-zota data from phase 1/2 explore44™ trial for dmd44 avidity to provide a first look at precision cardiology candidates and a glimpse at next-generation technology innovations via webcast event november 12, 2024 san diego , nov. 7, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today reported financial results for the third quarter ended september 30, 2024, and highlighted recent corporate progress. "we are executing three potentially registrational clinical trials in three rare diseases where there are limited or no therapeutic options available.
RNA Ratings Summary
RNA Quant Ranking